# Sub-cutaneous Infliximab in Inflammatory Rheumatic Disease

> **NCT05424926** · — · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 22 (actual)

## Conditions studied

- Rheumatoid Arthritis
- Spondyloarthritis
- Psoriatic Arthritis

## Interventions

- **OTHER:** collection of clinical parameters and blood sample

## Key facts

- **NCT ID:** NCT05424926
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-24
- **Primary completion:** 2023-12-14
- **Final completion:** 2024-12-16
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2026-04-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05424926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05424926, "Sub-cutaneous Infliximab in Inflammatory Rheumatic Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05424926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*